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1  | INTRODUC TION
In	 the	 past	 10	 years,	 the	 practice	 of	 medical	 oncology	 has	 been	
transformed	by	 the	development	of	 immune	checkpoint	 inhibitors	
for	anticancer	treatment.1	Immune	checkpoint	inhibitors	are	now	at	





death	1	 (PD-1).	 In	 a	 previous	 phase	 II	 clinical	 trial	 (hereinafter	 re-
ferred	to	as	the	primary	phase	II	study)	that	investigated	nivolumab	
therapy	in	stage	III/IV	or	recurrent	melanoma,	it	was	reported	that	
nivolumab	 was	 clinically	 beneficial.2	 The	 overall	 response	 rate	



























disease	 (PD)	 or	 unacceptable	 adverse	 events	 (AE)	were	 observed.	
The	criteria	 for	 study	drug	discontinuation	 included	 the	 following:	
complete	 response	 (CR)	 based	 on	 Response	 Evaluation	 Criteria	 in	
Solid	Tumors	 (RECIST)	guidelines	unless	 the	patient	was	expected	
to	experience	recurrence,	PD	based	on	RECIST	guidelines	with	no	










IV	 or	 recurrent	 malignant	 melanoma	 according	 to	 the	 Union	 for	
International	Cancer	Control-TNM	classification	(version	7).	Patients	
were	included	if	the	following	criteria	were	met:	age	≥20	years,	pa-
tients	with	 unresectable	 stage	 III/IV	 or	 recurrent	malignant	mela-
noma	 confirmed	by	 biopsy	 or	 cytology,	 previously	 untreated	with	
antineoplastic	 drugs	 (chemotherapy,	 molecular-targeted	 therapy	
or	 immunotherapy),	at	 least	1	measurable	 lesion	as	defined	by	the	
RECIST	guideline	version	1.1,	Eastern	Cooperative	Oncology	Group	
Performance	Status	 (ECOG-PS)	of	0-1,	 and	patients	 that	were	ex-
pected	to	survive	≥90	days.	In	the	case	of	preoperative	or	postop-
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tocol,	 and	 this	 study	was	 carried	 out	 following	 the	 ethical	 princi-





The	primary	 endpoint	was	 the	ORR,	which	was	 centrally	 assessed.	
The	 secondary	 endpoints,	 assessed	 in	 all	 study	patients	 and	 in	 the	
subpopulation	of	3-year	survivors,	included	OS,	progression-free	sur-
vival	 (PFS),	best	overall	 response	 (BOR),	disease	control	 rate	 (DCR),	
and	the	percent	change	in	the	sum	of	the	diameter	of	the	target	lesion.
A	 subgroup	 analysis	 was	 conducted	 to	 evaluate	 the	 ORR,	




evaluate	 the	 relationship	 between	 an	 early	 tumor	 response	 and	
subsequent	survival.	Post–hoc	subgroup	analyses	included	the	in-
vestigation	 of	ORR,	OS,	 and	 change	 in	 tumor	 diameter	 for	 each	
melanoma	 type	 (superficial	 spreading,	 acral	 lentiginous,	mucosal	
or	unknown).	 In	addition,	post–hoc	subgroup	analyses	were	per-
formed	 to	 investigate	ORR,	DCR,	OS	 and	PFS	 stratified	 by	 pro-
grammed	 death-ligand	 1	 (PD-L1)	 status	 (<1%	 or	 ≥1%),	 lactate	









The	 target	 sample	 size	was	≥20	patients	with	 at	 least	14	patients	
characterized	as	having	a	BRAF	wild-type	malignant	melanoma	and	
at	 least	 6	 patients	 with	 a	 BRAF	 mutant	 malignant	 melanoma.2,8 
Sample	size	calculations	were	described	in	full	in	the	primary	phase	
II	study.2
Efficacy	 endpoints	 were	 analyzed	 using	 the	 full	 analysis	 set,	
and	 the	 proportion	 of	 patients	 and	 the	 2-sided	 90%	 confidence	






PD.	We	conducted	a	post–hoc	 landmark	analysis	 to	evaluate	 the	










for	ORR	 and	DCR.	 Statistical	 analyses	were	 performed	using	 SAS	
software	(version	9.4,	SAS	Institute).
3  | RESULTS





cause	 the	patient	was	 found	 to	have	multiple	 cancers	 after	 initia-
tion	of	the	study.2	In	total,	there	were	ten	3-year	survivors	included,	







CR	 in	 4	 patients,	 PR	 in	 1	 patient,	 SD	 in	 4	 patients,	 unknown	 in	




65.3)	or	 acral	 lentiginous	 tumor	 type	 (28.6%	 [2/7	patients];	 90%	
CI:	 10.0,	 59.1).	 The	ORR	was	66.7%	 (2/3	patients;	 90%	CI:	 25.4,	
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The	 3-year	 OS	 rates	 of	 acral	 lentiginous	 or	 mucosal	 melano-
mas	 (28.6%	 [90%	CI:	 6.4,	 56.5]	 and	33.3%	 [90%	CI:	 7.4,	 62.9],	 re-
spectively)	were	lower	compared	with	that	of	superficial	spreading	





In	 Figure	 2,	 the	waterfall	 plot	 highlights	 the	maximum	 change	
in	 target	 lesion	 size	 from	 baseline	 (%)	 by	 tumor	 type	 (superficial	











diameter	 of	 another	 subgroup	 analysis.	 There	 was	 a	 clinical	 re-
sponse	 regardless	 of	 the	 presence	or	 absence	of	 the	BRAF V600 
mutation;	OS	rates	after	24	months	in	patients	with	BRAF	wild-type	
and BRAF	mutation	were	52.9%	and	66.7%,	 respectively,	 and	OS	
rates	after	36	months	were	41.2%	and	50.0%,	respectively	(Figure	
S1).	 In	addition,	PFS	rates	after	24	months	 in	patients	with	BRAF 
wild-type	and	BRAF	mutation	were	17.6%	and	62.5%,	respectively	
(Figure	S2).	The	PFS	rate	at	36	months	could	not	be	estimated	be-
cause	 none	 of	 the	 patients	were	 followed	 up	 for	 36	months.	 As	
for	PD-L1,	a	notable	effect	on	clinical	efficacy	was	observed	in	2	
TA B L E  1  Baseline	characteristics
Characteristics
















































TA B L E  2  Response	rate
Response




n % 90% CI n
BOR
CR 4 17.4 8.1-33.6 4
PR 4 17.4 8.1-33.6 1
SDa 7 30.4 17.4-47.6 4
PDa 7 30.4 17.4-47.6 0
Unknownc 1 4.3 1
ORR	(CR	+	PR) 8 34.8 20.8-51.9 5
DCR	
(CR	+	PR	+	SD)














serum	 LDH	 levels	 also	 greatly	 affected	 the	median	OS	 and	 PFS.	
A	serum	LDH	≤	the	upper	limit	of	normal	(ULN)	resulted	in	a	me-
dian	OS	 that	was	 not	 reached	 and	 a	median	 PFS	 of	 7.9	months.	










group.	 In	 the	 total	patient	group,	 the	most	common	 treatment-re-













The	 median	 OS	 reported	 here	 was	 similar	 to	 that	 of	 patients	 who	
received	nivolumab	monotherapy	 in	 the	CheckMate	067	study	 (32.9	





In	 this	 study,	 patient	 characteristics	 were	 generally	 consis-
tent	 with	 those	 who	 received	 nivolumab	 monotherapy	 in	 the	
CheckMate	067	study.9	However,	 the	percentage	of	tumor	types	
reported	in	Japan11	for	acral	lentiginous	(46%),	superficial	spreading	
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(23%)	 and	mucosal	 (10%)	 is	 different	 to	what	 has	 been	 reported	
in	 other	 countries	 (5%,	 54%	 and	 .4%	 respectively).12	 It	 has	 been	
reported	 that	acral	 lentiginous	 (50%-58%)13	 and	mucosal	 (15%)14 
melanoma	are	common	subtypes	in	Asian	countries.	Thus,	the	per-
centage	of	 tumors	 that	are	acral	 lentiginous	or	mucosal	 is	higher	
in	East	Asian	 countries,	 including	 Japan,	 than	 in	other	 countries.	
In	 the	present	study,	 the	distribution	of	acral	 lentiginous	 (29.2%)	



























None	 of	 the	 patients	 with	 mucosal	 melanomas	 were	 confirmed	
to	 be	 PD-L1	 positive,	 which	 is	 consistent	with	 previous	 reports	










































TA B L E  3  Subgroup	analysis	of	clinical	efficacy
All patients (n)
ORR DCR OS PFS
n (%) [90% CI] n (%) [90% CI] Median (mo) Median (mo)
BRAF
Wild-type 17 4	(23.5)	[11.0,	43.3] 10	(58.8)	[39.3,	75.9] 26.9 4.2
Mutant 6 4	(66.7)	[34.7,	88.3] 5	(83.3)	[49.8,	96.2] NR 26.2
PD-L1a
≥1% 3 2	(66.7)	[25.4,	92.2] 3	(100.0)	[52.6,	100.0] NR 26.2
<1% 14 4	(28.6)	[13.5,	50.6] 8	(57.1)	[36.0,	75.9] 14.0 3.5
LDH
≤ULN 16 6	(37.5)	[20.8,	57.8] 12	(75.0)	[54.5,	88.2] NR 7.9
>ULN 7 2	(28.6)	[10.0,	59.1] 3	(42.9)	[18.6,	71.1] 11.7 1.4
Tumor	diameter	at	baseline	(mm)
≤21.950b 5 3	(60.0)	[27.2,	85.7] 4	(80.0)	[43.5,	95.4] NR 26.6
>21.950b	and	≤64.615c 12 3	(25.0)	[10.5,	48.7] 8	(66.7)	[43.1,	84.1] 29.9 4.9







All patients (n = 24) 3‐y survivors (n = 10)







Overall 20	(83.3) 3	(12.5) 10	(100.0) 0
Vitiligo 9	(37.5) 0 7	(70.0) 0
Hypothyroidism 6	(25.0) 0 2	(20.0) 0
Malaise 6	(25.0) 0 4	(40.0) 0
Pruritus 6	(25.0) 0 3	(30.0) 0
Nausea 3	(12.5) 0 1	(10.0) 0
Weight	decreased 3	(12.5) 0 1	(10.0) 0
Appetite	decreased 3	(12.5) 0 1	(10.0) 0
Arthralgia 3	(12.5) 0 2	(20.0) 0
Rash	maculo-papular 3	(12.5) 0 2	(20.0) 0
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